July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.
Anuraag Kansal, PhD
Advertisement
Articles by Anuraag Kansal, PhD
An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Inside Myeloma’s Evolution From Death Sentence to Cure
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia
5